Humacyte Debt To Equity from 2010 to 2024

HUMAW Stock  USD 1.85  0.02  1.09%   
Humacyte Debt To Equity yearly trend continues to be fairly stable with very little volatility. Debt To Equity is likely to outpace its year average in 2024. Debt To Equity is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. View All Fundamentals
 
Debt To Equity  
First Reported
2010-12-31
Previous Quarter
3.04244796
Current Value
3.19
Quarterly Volatility
1.09021874
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Humacyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Humacyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.7 M, Interest Expense of 1.1 M or Selling General Administrative of 21.1 M, as well as many indicators such as Price To Sales Ratio of 96.95, Dividend Yield of 0.0 or PTB Ratio of 22.77. Humacyte financial statements analysis is a perfect complement when working with Humacyte Valuation or Volatility modules.
  
Check out the analysis of Humacyte Correlation against competitors.
For more information on how to buy Humacyte Stock please use our How to Invest in Humacyte guide.

Latest Humacyte's Debt To Equity Growth Pattern

Below is the plot of the Debt To Equity of Humacyte over the last few years. It is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. Humacyte's Debt To Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Humacyte's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.00 %10 Years Trend
Slightly volatile
   Debt To Equity   
       Timeline  

Humacyte Debt To Equity Regression Statistics

Arithmetic Mean0.44
Coefficient Of Variation247.75
Mean Deviation0.71
Median(0.01)
Standard Deviation1.09
Sample Variance1.19
Range3.1993
R-Value0.63
Mean Square Error0.77
R-Squared0.40
Significance0.01
Slope0.15
Total Sum of Squares16.64

Humacyte Debt To Equity History

2024 3.19
2023 3.04
2022 0.25
2021 0.22

About Humacyte Financial Statements

Humacyte investors use historical fundamental indicators, such as Humacyte's Debt To Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Humacyte. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Debt To Equity 3.04  3.19 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Humacyte Stock Analysis

When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.